News | November 05, 2021
UK authorises first Covid-19 pill
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
Marketing authorisation holders are advised to submit any type IB variations or groupings of type IBs and type IAs by 3rd December 2021 for a start of procedure in 2021
Generalized pustular psoriasis is characterized by episodes of widespread eruptions of painful, sterile pustules
Kymriah, the first-ever FDA-approved CAR-T cell therapy, is currently available in 30 countries in one or more indications
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
A growing number of studies have shown the benefit of a third dose of Covid-19 vaccine in immunocompromised subjects
It is the first orally administered therapy for the treatment of two types of ANCA-associated vasculitis approved in Japan
CuraTeQ Biologics is on track for filing a second oncology biosimilar
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
In participants 5 to 11 years of age, the vaccine was safe, well-tolerated and showed robust neutralising antibody responses. Results in children under 5 years of age are expected as soon as later this year
Subscribe To Our Newsletter & Stay Updated
